Blau Farmacêutica: Net income jumped 52% on stable revenue, margin gains, and divestment proceeds

About this update from Blau Farmaceutica Sa

Net revenue was stable at BRL 475 million in 3Q25, with strong Aesthetics growth and improved gross margin for the eighth consecutive quarter. Net income surged 52% year-over-year, driven by Prothya divestment gains, while CAPEX and R&D investments increased significantly.Original document: This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.

View stock analysis, news, and events for Blau Farmaceutica Sa